<![CDATA[Novo Nordisk A/S - Press Releases]]><![CDATA[EFSD/Novo Nordisk partnership for diabetes research in Europe]]><![CDATA[Novo Nordisk extends programme of free insulin and diabetes care to reach 700 children in Bangladesh]]><![CDATA[New study results show that patients have higher treatment satisfaction with liraglutide compared to exenatide]]><![CDATA[The 4-T study of intensified insulin regimens shows excellent three-year glucose control with low risk of hypoglycaemia in type 2 diabetes]]><![CDATA[New data shows that type 2 diabetes patients who start insulin therapy with once-daily NovoMix® 30 achieve significantly greater HbA1c reduction than with insulin glargine. 1]]><![CDATA[New data shows that patients with type 2 diabetes improve their blood sugar control when switched to Victoza® from Byetta®]]><![CDATA[Novo Nordisk opens new research centre in Seattle]]><![CDATA[Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities]]><![CDATA[The Lancet publishes direct comparison study between liraglutide and exenatide]]><![CDATA[Two-year data show investigational drug liraglutide more effective at lowering blood sugar than glimepiride]]><![CDATA[New study first ever to directly compare once-daily Levemir® with another basal insulin analogue]]><![CDATA[New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen®]]><![CDATA[Novo Nordisk reaches settlements with the US Securities and Exchange Commission and Department of Justice regarding Oil-for-Food activities]]><![CDATA[Novo Nordisk and VLST Corporation announce collaboration agreement]]><![CDATA[Children in the world’s poorest countries to get free insulin and access to diabetes care]]><![CDATA[Urgent need for social and psychological support for young people with diabetes]]><![CDATA[Novo Nordisk invests close to 400 million US dollars in new insulin production plant in China]]><![CDATA[Novo Nordisk, Cellartis and Lund University enter into a collaboration to develop insulin-producing cells from stem cells for the treatment of diabetes]]><![CDATA[New data from head-to-head phase 3 trial demonstrate that liraglutide is more effective than exenatide in treatment of type 2 diabetes]]><![CDATA[Novo Nordisk and Innate Pharma swap product rights]]>